FDA to Discuss Next Round of Device User Fees
Published Date: 7/8/2026
Notice
Summary
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
Analyzed Economic Effects
6 provisions identified: 4 benefits, 1 costs, 1 mixed.
New Pre-Submission Fee With Credit
FDA proposes a new fee for initial Pre-Submissions, with sponsors later receiving a corresponding credit on certain related subsequent marketing submission fees. Under the proposal, FDA will aim to provide written feedback on at least 90% of Pre-Submissions within 70 days (or 5 days before a scheduled meeting) for up to 5,000 Pre-Submissions per fiscal year, and introduce a faster Focused Follow-Up Pre-Submission with written responses within 45 calendar days.
Firm Timelines: PMA and 510(k) Goals
FDA proposes shared outcome goals for average Total Time to Decision: 285 calendar days for original PMA and panel-track supplement submissions throughout FYs 2028 through 2032, and a 510(k) shared outcome goal that ramps from 128 calendar days in FY 2028 to 112 calendar days by FY 2032. These goals are intended to continue reducing review times and speed patient access to devices.
De Novo Decision Timing and Meetings
FDA proposes to maintain a De Novo decision goal of 90% within 150 FDA days, introduce a structured Introduction Meeting within the first 30 FDA days of review, and allow issuance of a 'Not Grantable' letter with a final determination to decline or grant within 75 to no more than 90 calendar days after receipt of the response.
User Fees Continue; RWE Funds Restricted
MDUFA VI would continue FDA's authority to collect device user fees for FYs 2028 through 2032 to support the review process. The draft commitment letter specifies that user fee revenue will be devoted solely to premarket Real-World Evidence (RWE) activities.
TAP Program Expansion and CMS Collaboration
FDA proposes to transition the TAP pilot to a sustainable, full Total Product Life Cycle (TAP) program covering all product areas with voluntary enrollment targeted to eligible devices across all Offices of Health Technology no later than October 1, 2027. TAP will focus on enhancing the Breakthrough Device review experience and includes focused engagement between FDA and CMS for technologies where a new coverage determination would be beneficial.
International Harmonization Pilot
MDUFA VI proposes a pilot where the same device with the same intended use is submitted simultaneously to FDA and at least two other medical device regulatory authorities to support coordinated premarket review; results will be evaluated and published by September 30, 2030.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
Previous / Next Documents
Previous: 2026-13777 — Notice of Request To Release Property at the Dare County Regional Airport Manteo, North Carolina (MQI)
The Dare County Airport Authority wants to free up 8.74 acres of land at Dare County Regional Airport so the county can use it for public works instead of airport stuff. The FAA is asking the public to share their thoughts by August 7, 2026, before deciding. This change won’t affect airport operations but will help the county redevelop the land for local needs.
Next: 2026-13779 — Gulf of America Outer Continental Shelf Oil and Gas One Big Beautiful Bill Act Lease Sale 3
On August 12, 2026, the government will hold a big oil and gas lease sale in the Gulf of America’s Outer Continental Shelf. Companies wanting to drill can submit bids by August 11, with the sale following strict rules to keep things fair and clear. This sale could bring new energy projects and money to the region, affecting businesses and communities tied to offshore drilling.